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esponsibility of InstAbstract RNA interference (RNAi) has been harnessed to produce a new class of drugs for treatment
of various diseases. This review summarizes the most important parameters that govern the silencing
efﬁciency and duration of the RNAi effect such as small interfering RNA (siRNA) stability and
modiﬁcation, the type of delivery system and particle sizing methods. It also discusses the predominant
barriers for siRNA delivery, such as off-target effects and introduces internalization, endosomal escape
and mathematical modeling in RNAi therapy and combinatorial RNAi. At present, effective delivery of
RNAi therapeutics in vivo remains a challenge although signiﬁcant progress has been made in this ﬁeld.
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K. Gao, L. Huang2141. Introduction
RNA interference (RNAi) is a powerful and versatile gene-
silencing process in which double-stranded RNA (dsRNA) triggers
the sequence-speciﬁc cleavage of mRNA transcripts. In 2001,
Tuschl and colleagues1,2 demonstrated that RNAi occurs in
mammalian cells and became the ﬁrst to apply small interfering
RNAs (siRNAs) in guiding the sequence-speciﬁc suppression of
gene expression. Methods of mediating RNAi effects involve
siRNA, short hairpin RNA (shRNA), bifunctional shRNA and
microRNA (miRNA). Table 1 summarizes the most important
features of each category. Conceptually, target speciﬁc RNAi
agents including DNA encoding siRNA/shRNA can also be
applied in combination with immune modulating agents or small
molecules to improve the efﬁcacy of cancer treatment. As with any
new therapeutic paradigm, there are a multitude of issues to be
addressed in order to translate RNAi technology (siRNA, shRNA,
bi-functional RNA and miRNA) from the laboratory into the
clinic.
Numerous siRNAs effectively modulate in vivo tumor growth
via intratumoral, ex-vivo or systemic routes of application14–17.
Appropriate pharmaceutical considerations at different levels of
clinical drug development, e.g., nucleic acid design18,19 and
nucleic acid formulation20, must be applied when translating
RNAi into a therapeutic platform. However, the clinical use of
RNAi has been severely limited by an inability to target these
molecules to cell populations in vivo because of their instability,
limited cell uptake and poor pharmacokinetic proﬁles. Here we
focus on the major barriers to siRNA delivery (Fig. 1) (siRNA
stability, off-target effects, internalization and endosomal degrada-
tion) and the efforts to overcome them such as siRNA modiﬁca-
tion, use of delivery systems, particle size control, mathematical
modeling and the use of combinations of shRNAs.2. siRNA stability and modiﬁcation
Because of their double-stranded structure, siRNAs are recognized
as “foreign” by the innate immune system. Thus successful in vivo
application of siRNAs requires improvements in their biostability
and cellular delivery21–25. One of the ﬁrst biological barriers
encountered by administered, naked siRNAs is represented by the
nuclease activity in plasma and tissues. Although dsRNAs,
including siRNAs, are more stable than their single stranded
counterparts, they can still be degraded and must be protected from
nuclease attack26. To this end, efforts have been made to
chemically modify siRNAs to reduce their susceptibility to RNases
and improve their in vivo properties. More detailed information
can be found in Table 2.
siRNA duplexes have been modiﬁed in numerous ways but the
reported results remain contradictory in terms of their ability to
inhibit gene expression. Chemically modiﬁed siRNAs work
through only one pathway and must interact with a number of
different cellular proteins, many or all of which may be sensitive to
the modifying group. Because endogenous duplex RNAs control
important physiological processes, a modiﬁed synthetic RNA may
perturb this endogenous machinery. Certainly, the future use of
siRNA as therapeutic tools will involve sophisticated medicinal
chemistry to improve both their biodistribution to tissues and
uptake by speciﬁc cell types. Reduction in off-target effects and
enhancement of the efﬁciency of silencing by the duplexes thatultimately reach the target cells continue to be goals of chemical
modiﬁcation to these therapies.3. Delivery systems
To effectively trigger RNAi and induce gene silencing, siRNAs
must be delivered to the cytoplasm of the target cell. This delivery
is limited by several extra and intracellular barriers not least of
which is the cellular membrane that is relatively impermeable to
siRNAs because of their negative charge and size. The systemic
administration of siRNAs results in primary localization to the
liver and, because of the lack of targeting, has the potential to
trigger many unwanted side effects. Although these can be
alleviated to some extent by local administration, the widespread
development of siRNA therapeutics requires a focus on targeting
through the design of novel nucleic acid delivery systems104.
An ideal gene delivery vector should be effective, speciﬁc, long
lasting and safe. An ideal delivery vehicle must be able to
selectively and differentially target tumors as opposed to normal
tissue, distribute homogeneously throughout tumor tissues and
penetrate tumor cells following systemic administration. Despite
signiﬁcant advances in the past two decades, the safe and efﬁcient
delivery of therapeutic nucleic acids for gene therapy is still in its
infancy.
Vectors can generally be categorized into viral and non-viral
vectors and are selected to achieve high efﬁcacy as well as on the
basis of their safety and biocompatibility. Viral vectors are most
known for their high delivery and transfection efﬁciencies and are
distinguished by their size and transgene capacity, target, perfor-
mance, duration of required expression, induction of an immune
response and safety105,106. The development of non-viral vectors
has lagged behind that of viral vectors but they are being
increasingly trialed mainly because of their reduced immunotoxi-
city and side-effects107,108.
3.1. Viral vectors
Retroviruses, lentiviruses, baculoviruses, adenoviruses and adeno-
associated-viruses (AAVs) have been utilized for delivery of
polynucleotides to cells109. Retroviruses offer the advantages of
providing life-long expression of shRNA transgenes and transdu-
cing siRNA to actively dividing cells. Both lentiviruses and
baculoviruses can deliver large quantities of genetic information.
Comparatively, adenoviral vectors have a short duration of action
and exhibit dose-dependent liver toxicity. However, AAVs can
transduce both dividing and non-dividing cells. Several studies
have shown that viral-based siRNA or shRNA administered by
injection may potentially reach the myocardium and mediate
therapeutic RNAi in the heart110,111. Finally, viral vectors are
highly efﬁcient, but limited in the amount of genetic material they
can carry, and their tendency to initiate immune responses.
3.2. Non-viral vectors
Due to the limitations of viral delivery systems, non-viral vectors
are emerging as a major focus in the ﬁeld of gene therapeutics
since they have the potential to overcome obstacles to successful
delivery. Various strategies for non-viral delivery of siRNAs to
speciﬁc tissues and organ systems have been developed and are
described in Table 3. The most extensively studied systems
are cationic lipid- and polymer-based systems which include
Table 1 Summary of si/sh/bi/miRNAs.
Item Small interfering RNA (siRNA) Short hairpin RNA (shRNA) bi-Functional shRNA3 microRNAs (miRNA)
Characteristics 1. Regular 21–25 bp oligonucleotides, if
19–21 nt length and 2 nt 3′ overhang
siRNAs are delivered into cells, they can
directly engage with the RNAi
machinery, without any processing steps.
2. No siRNA in mammals, only plants.
3. Regulate mRNA via perfect
complementarity.
Pre-shRNA with a hairpin-like stem-loop
structure synthesized in the nuclei of cells is
further processed and transported to the
cytoplasm by exportin 5. There it forms a
double-stranded siRNA with 2 nt 3′ overhangs
and is incorporated into the RISC for activity4.
1. Takes advantage of the gene silencing
machinery within cells to achieve higher
efﬁcacy and greater durability compared to
siRNA, and a more rapid onset of gene
expression silencing.
2. The design of the bi-functional shRNA
expression unit has fully-matched passenger
and guide strands that enable cleavage-
dependent RISC loading.
3. It also includes a mis-matched passenger
strand that enables cleavage-independent
RISC loading.
1. Mature miRNA sequence (21–
25 bp oligonucleotides)
containing one arm of the stem-
loop structure.
2. Pre-miRNA is processed from
pri-miRNA and transported
from the nucleus to the
cytoplasm by Exportin-5.
3. A class of endogenous gene
regulators.
4. Single miRNA can regulate
multiple mRNA targets via
binding with a number of
mismatches.
Generation 1. Dcr-2/R2D2 complexes generate
siRNAs.
2. Dicer transforms double-strand RNA
(dsRNA) to siRNA and transfers the
processed products to the RISC5,6.
1. The TRBP/PACT/Dicer complex is
required to modify shRNA or long dsRNA
to the appropriate size and form, enabling
loading into RISC.
2. The shRNA are presumably processed in a
manner similar to that of the microRNA
maturation pathways.
1. Dcr-1/Loqs complexes generate
miRNAs with approximately 21
nucleotide mature duplexes.
2. Dicer processes pre-microRNA
to mature miRNA.
Mechanism The RISC with a single-stranded guide strand
siRNA is able to execute multiple rounds of
RNA interference.
1. The shRNA expression units can be
incorporated into varieties of plasmids and
viral vectors for delivery and integration.
2. shRNA in the RISC should, in principle,
carry out the same function as siRNA, but
more durably.
The bi-functional shRNA approach mimics the
natural process by mediating the knockdown of
target mRNA through multiple RNAi pathways
and complexes. Bi-functional shRNA also
inhibits translation through mRNA sequestration.
miRNAs with a perfect or near-
perfect complementarity to the
target RNA have also been
associated with mRNA degradation
and translational inhibition.
Research
demonstrations
Animal studies with siRNA inhibitors for
RRM2 show efﬁcacy7 and safety in non-
human primates8.
shRNA for the treatment of hepatitis B was also
approved for clinical trial by the FDA.
miRNA functionality has been
conﬁrmed in three tumor types
(ovary, breast, and lung)
Similarity Ago protein complexes loaded with passenger strand of siRNA or miRNA seek out complementary target sites in mRNAs, endonucleolytically
cleaves mRNA to initiate mRNA degradation9,10. Other Ago protein containing complexes without endonucleolytic activity induce translation
repression through mRNA sequestration in processing bodies (p-bodies)11–13.
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Figure 1 Overview of the main biological barriers for RNAi gene silencing. For in vivo application, siRNAs (miRNAs/shRNAs) can be
formulated into nanosized carriers that should be large enough to avoid renal clearance, but small enough to extravasate through the capillary
endothelium to reach the target tissues. Moreover, the siRNA carrier must be able to evade uptake by the mononuclear phagocyte system and
protect the siRNAs (miRNAs/shRNAs) against circulating RNases. Once the carrier has reached the target cell, it must deliver the siRNAs
(miRNAs/shRNAs) to the cytoplasm. This process typically involves cellular uptake through endocytosis, followed by escape from the endosome
and carrier dissociation in the cytosol. ECM: extracellular matrix, NPC: nuclear pore complex, TGS: transcriptional gene silencing.
K. Gao, L. Huang216liposomes and nanoparticles. In most cases, their cationic nature
contributes to both the formation of complexes with polyanionic
nucleic acids and the interaction with negatively charged cell
membranes138. Non-viral vectors are generally superior to viral
vectors in safety, particularly because of their low risk of infection.
The simplicity of use and the possibility of large-scale production
of these vectors are also advantageous. A variety of strategies are
now being developed to improve the efﬁciency of non-viral
vectors including the use of lipid-based systems, chitosans,
polymeric micelles, siRNA conjugates and peptide delivery
systems. However, the efﬁciency of gene expression mediated
by these vectors is less than by viral vectors due to their limited
ability to reach and cross the nuclear membrane.4. Particle sizing methods
For intravenous administration of siRNA polyplexes, particle size
is a particularly important parameter. To prevent clogging of
capillaries, the upper end of a size distribution becomes important.
Additionally, extravasation of siRNA complexes through fenestra-
tions of tumor capillaries dictates certain size requirements4. After
intravenous administration, very small particles (o6 nm) are
quickly eliminated through renal excretion, whereas larger parti-
cles are taken up by cells of the monomolecular phagocytic system
which are predominantly present in the liver and spleen. Particles
with diameter of 150–300 nm are distributed within the liver and
spleen whereas those with diameter of 30–150 nm are found in the
bone marrow, heart, kidney and stomach. Thus the ability toreliably determine the size of siRNA polyplexes is key to their
rational design, formulation, and safe application in vivo.
At the present time, there is no standardized technique for
measuring the size of non-viral vectors such as polyplexes. Four
different methods (Table 4) have been evaluated for their
suitability in characterizing homogeneous and heterogeneous
siRNA polyplexes but no one method is completely satisfactory.
As a result, Troiber et al.139 recommended a combination of at
least two methods to determine the heterogeneity of samples, one
of which should be microscopic. Laser dynamic light scattering
has been widely used but is insensitive to the heterogeneity of the
particle population. Recent advances in using imaging techniques
to track Brownian motion and hence to calculate particle size using
the Stoke-Einstein equation is very attractive140,141.5. Internalization
Internalization pathways determine the intracellular fate of com-
plexes. Reineke et al.142 investigated the mechanisms involved in
cellular internalization and trafﬁcking and revealed that
carbohydrate-based poly(glycoamidoamine) polymers can bind
and compact nucleic acids into polyplexes that facilitate effective
intracellular pDNA delivery with low toxicity. Zhang et al.143
summarized the uptake mechanisms of non-viral gene delivery
systems and classiﬁed uptake mechanisms of non-viral gene
delivery, factors for pathway selection and the inhibitors or tools
for the study of these pathways. Ming et al.144 elucidated
internalization mechanisms through the use of pharmacological
and genetic inhibitors of endocytosis and found that that
Table 2 siRNA modiﬁcation.
Classiﬁcation Modiﬁcation Demonstration
Base modiﬁcations 4-Thiouridine, 5-bromo-, 5-iodo-, 5-(3-aminoallyl)-
uridine, or inosine
No remarkable differences in silencing activity27
5-Bromouridine, 5-iodouridine, 2,6-diaminopurine, and
N-3-methyl-uridine
May reduce silencing activity28
2-Thiouridine (s2U), pseudouridine (ψ), and
dihydrouridine (D)
Modulate siRNA duplex silencing potency29
Modiﬁed with propynyl functionalities at the C-5
position of pyrimidine nucleobases
Strong stabilizing effects and negative effects in RNAi
activity30
Modiﬁed with methyl functionalities at the C-5 position
of pyrimidine nucleobases
No difference in gene silencing30
The 2,4-diﬂuorotoluyl ribonucleoside (rF) No difference in gene silencing31
Internal uridine to rF substitutions Slightly less destabilizing, effectively silences and has
better nuclease resistance in serum31
Pseudouracil or 2-thiouracil, 5-methyl-C, N6-methyl-A
pseudouridine 40
Inhibits immunostimulation32,33
Sugar modiﬁcations 2′-Fluoro Well tolerated in siRNA applications27,28,34–36
Partial modiﬁcation of siRNA strands with 2′-O-Me
(less than 8 nt)
Better performance of RNAi36
Completely modiﬁcation with 2′-O-Me No interference activity28
Position speciﬁc 2′-O-methylation Reduced off-target effects14
2′-O-Me uridine or guanosine Noninﬂammatory and potent silencing of its target
mRNA37
2′-O-MOE modiﬁcation Less active siRNA constructs38
2′-O-allyl modiﬁcation Well tolerated39
2′-Deoxy-2′-ﬂuoro-β-D-arabino Longer half-life in serum and more potent40,41
DNA modiﬁcation Reduced off-target effects42
2′-Deoxy bases T or dU bases Prevents immune detection43
Locked nucleic acids Enhances serum half-life, reduces immunostimulatory
and off-target effects44
2′-O-(2,4-dinitrophenyl) RNAs Outperform previous generation of antisense and
unmodiﬁed siRNAs45–47
Poly-2′-O-(2,4-dinitrophenyl)-oligoribonucleotide Promising new gene silencing platform45–47
4′-Thio modiﬁed the ring oxygen Thermally stable duplex and high nuclease
resistance48–50
Combination of 4′-thioribose with 2′-O-Me and 2′-O-
MOE modiﬁcations
Potency for silencing in cell culture42
2′,3′-Seconucleosides Increases the ﬂexibility of nucleic acid
analogs29,51,52
Backbone modiﬁcations Phosphorothioate (PS) modiﬁcations Prolong the life of the duplex35,39,53
Boranophosphate linkage modiﬁcation Higher efﬁcacy54
Peptide nucleic acids Improved performances55,56
Morpholino oligomers More potent55,56
Architecture modiﬁcations asiRNA, asymmetric siRNAs Reduces off-target effects57,58
Blunt-ended siRNA Better performance59
Dicer-substrate siRNA (DsiRNA) Use in CNS disorders60
Small internally segmented interfering RNAs (sisiRNA) Highly functional61
Two guide strands (dgRNAs) Minimizes non-speciﬁc effects62
Single-stranded antisense siRNAs (sssiRNAs) Effective in silencing genes in HeLa cells63
Short hairpin-type duplexes (shRNAs) Displays high stability64
Dumbell-shaped nanocircular RNAs Slowly releases dsRNAs65
Modiﬁcations to Overhangs
and Termini
Modiﬁed with either an inverted deoxy a basic residue
or an amino group
No reduction in activity39,59,66,67
25–30-nt in length 100-fold more potent and more immunogenic66
2-nt 3′-overhang Increases the stability68
Aromatic compounds at 3′-overhangs Better silencing activity69
RNA-3′-PNA chimeras Efﬁcient gene silencing70
The modiﬁcation on the sense strand Increases persistence of the activity70
Modiﬁcation on both strands Enhances nuclease resistance in serum70
Thymidine dimers consisting of a carbamate
or urea linkage at 3′-end
78 and 37 times more efﬁcient than non-modiﬁed
siRNA 71
5′-Omethylated siRNA duplexes siRNA strand selection67
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Table 2 (continued )
Classiﬁcation Modiﬁcation Demonstration
siRNA conjugation Cholesterol Long duration, effects tissue distribution and uptake,
decreases side effects72,73
Cell penetrating peptides (CPP) Demonstrates that endocytosis is a major route of
internalization, signiﬁcant uptake of siRNAs and
efﬁcient suppression of the target genes, undesirable
immune responses74–88
Polyethylene glycol (PEG) Much higher levels of siRNA stability78,82
Quantum dot Visualization of siRNA entry, transport, and
endosomal escape to the cytoplasm in living cells89
Iron oxide Dual diagnostic imaging and therapeutic drug
delivery90
Gold Elevated melting temperatures91–96
Mesoporous silica nanoparticle Effective siRNA protective effect and negligible
cytotoxicity97.
Magnetic silica spheres Controlled particle diameter and large nanopore
size98.
Carbon nanotubes High surface to volume ratios enabling modiﬁcations
with surface functional groups that can mediate the
speciﬁc targeting of therapeutic agents, unique
electronic, mechanical and structural properties,
chemical stability99,100
Speciﬁc ligands (aptamers, antibodies, peptides, sugar
molecules, vitamins and hormones)
Cell recognition through speciﬁc interactions
minimizes the potential adverse effects and reduces
the dose required for therapeutic effects101–103
K. Gao, L. Huang218oligonucleotides delivered by lipoplexes enter cells partially by
membrane fusion, a mechanism which accounts for the functional
induction of the target gene. In contrast, polyplexes are internalized
byunconventional endocytotic pathways that donot require dynamin
or caveolin. Through the use of pharmacological and genetic
inhibitors of endocytosis, they showed how synthetic RNAs access
their pharmacological targets within cells. It is hoped these studies
will contribute to the rational design of novel delivery systems with
superior transfection efﬁciency and low toxicity.
Despite the progress described above, a comprehensive under-
standing of uptake mechanisms is lacking because only simple
molecules have been studied. Moreover, the process by which the
homogeneity of a complex is guaranteed inﬂuences how the
characteristics of a complex and its uptake pathway are related.
However, an understanding of how cationic carriers assist in the
processes of internalization and trafﬁcking is essential to the design
of superior non-viral gene complexes. With an ability to control the
heterogeneity of complexes, an increasing interest in new nanofab-
rication methods that also allow the control of particle dimensions
has emerged145. The uptake pathways of a non-viral gene complex
are usually controlled not only by the gene/carrier interaction but
also by the interaction between the complex and its target cells.
6. Endosomal escape
Upon escape from the endosome, many formulations such as
PEGylated liposomes allow direct release of siRNA into the
cytoplasm. However, since endosomes do not all rupture at the
same time, the release of siRNA into the cytoplasm could be
sustained for longer than required for efﬁcient gene silencing at a
relatively low concentration. The release from endosomes may
therefore result in prolonged effects of siRNA.
The kinetics of gene silencing by unmodiﬁed and nuclease-
stabilized siRNAs has been recently described in both in vitro andin vivo experiments by Bartlett and Davis146,147. The ability of
siRNA or an siRNA carrier complex to escape from the endosomal
compartment can be a limiting step in their gene silencing
efﬁciency. Modiﬁcations to delivery techniques through the use
of pH-sensitive nanogels or carbonate apatite, the application of
photochemical internalization (PCI), the use of an inﬂuenza-
derived fusogenic peptide and addition of a fusogenic peptide to
a siRNA loaded dex-HEMA-co-TMAEMA nanogel dispersion has
been shown to enhance endosomal escape. In addition, Raem-
donck et al.148,149 have revealed the value of biodegradable
hydrogels for controlled nucleic acid delivery. It should be clear
that the optimal siRNA release proﬁle to achieve sustained gene
silencing depends on whether the target cells are slowly dividing,
rapidly dividing or non-dividing. The expression level of the target
gene will also inﬂuence the concentration of siRNA needed in the
cell cytoplasm to achieve maximum gene silencing effects.7. Off-target effects
Despite initial results showing excellent speciﬁcity in RNAi
mediated gene silencing, studies over the past eight years have
revealed that siRNA and shRNA can cause multiple effects other
than the intended mRNA suppression. These off-target effects can
be speciﬁc or non-speciﬁc. The former are mediated by partial-
sequence complementarity of the RNAi construct to mRNAs other
than the intended target. The latter include a wide variety of
immune and toxicity related effects, a dose dependent tissue
response and neuronal degeneration that are intrinsic to the RNAi
construct itself or to its delivery vehicle.
Aagaard and Rossi150 ﬁrst suggested that off-target effects were
of particular concern with RNAi therapeutic modalities and
indicated that novel-protein arrays could be better suited to
elucidate the effects of siRNA on cellular protein expression
Table 3 Key concepts of siRNA delivery as published over the last three years.
Delivery method/system Description
Sheddable ternary nanoparticles Tumor acidity-targeted siRNA delivery112
Lyophilized siRNA nanosome formulations Evaluate the stability of lyophilized siRNA formulations113
Multicomponent synthetic polymers with viral-mimetic
chemistry
Mimics virus modular components114
ScFv-mediated siRNA delivery Treat Her2+breast cancer115
Targeted Polymeric Micelles for siRNA Intravenous injection cancer treatments116
NDs is as a vehicle for the intracellular delivery of nucleic
acids
Review117 mention
Biscarbamate cross-linked low molecular weight PEI For arthritis therapy118
Sequence-deﬁned assembly and each functional
substructure for a speciﬁc and efﬁcient gene silencing.
Good tolerability in vivo and the absence of accumulation in nontargeted tissues119
Carbonate apatite-mediated delivery of siRNA Sensitization of a human cervical cancer cell line to doxorubicin- and paclitaxel120
CADY/siRNA complexes Stable and can be applied to cultured cells121
Dendronized Gold Nanoparticles Possess the beneﬁts of polymeric delivery vehicles122
Glutathione-responsive nano-transporter Silencing the mRNA expression of Ras123
Gelatin nanospheres The prolonged time period of gene suppression124
A series of cationic lipobenzamides Intrinsic anticancer activity and suitability for use in siRNA delivery125
Lipid modiﬁed triblock PAMAM-based nanocarriers Especially useful for the treatment of multi-drug resistant cancers126
Bioresponsive and endosomolytic siRNA-polymer
conjugate
Stable and release of siRNA at endosomal pH127
PAMAM dendrimer conjugates with cyclodextrins Treat RFP/B16F10-bearing mice3
GC–PEI NPs Review128 mention
Hemiﬂuorinated polycationic lipids Remarkable serum compatibility129
PEI-based vector systems Pulmonary application130
Glycopolymer-stabilized gold nanoparticles Complexation with DNA5
Combining siRNA nanogels and PCI Prolong gene silencing106
BBN-oligonucleotide conjugate GRPR mediated endocytosis6.
Chlorotoxin bound magnetic nanovector Cancer cell targeting, imaging, and siRNA delivery131.
Oral Protein Therapy The personalized therapy of common diseases8
pH-sensitive carbonate apatite Highly promising for pre-clinical and clinical cancer therapy132
Amphoteric Agmatine Containing Polyamidoamines Plasmid DNA in vitro and in vivo Delivery133
Biodegradable dextran nanogels The intracellular delivery of small interfering RNA106
Dendrimer The structural behavior and thermodynamics of the complexation of siRNA7.
Poly(amine-co-esters) Biodegradable, higher transfection efﬁciencies, extremely low cytotoxicity, and
promising nonviral vectors for safe and efﬁcient DNA delivery in gene therapy134
Multilayered siRNA-Coated gold nanoparticles Released gradually and extended gene-silencing effects9
A biodegradable amphiphilic and cationic triblock
copolymer
Signiﬁcantly inhibited tumor growth in a BT474 xenograft murine and
modelmicelleplex siRNA delivery in cancer therapy135
siRNA/carbonate apatite nano-composites Effective knockdown of cyclin B1 gene10
A polymeric vector incorporating endosomolytic
oligomeric sulfonamide
pDNA helps effectively form nanosized siRNA particles and that OSA enhances
speciﬁc gene Silencing136.
Lipid derivatives carrying amino and triazolyl groups Compatible with the RNA interference machinery11
Functionalized Lipopolyamine Delivery of siRNA to the mouse lung137
GPI modiﬁcation Open the possibility for oral non-viral gene therapy12.
CADY self-assembling peptide-based nanoparticles Direct translocation as major cellular uptake13
Fluorescent PAMAM dendrimer Bioimaging and transfection study27
An injectable scaffold Sustained local delivery of siRNA28.
Amino-ethoxilated ﬂuorinated amphiphile: Use as ssDNA vector29.
Tyrosine trimers stabilize pDNA and siRNA polyplexes Intratumoral treatment of neuroblastoma-bearing mice30.
Achieving efﬁcient RNAi therapy: progress and challenges 219proﬁles and provide a superior method for screening siRNA.
Identiﬁcation of very potent or hyperfunctional siRNAs could
contribute to reducing unwanted off-target effects since these
siRNAs would function at sub-nanomolar concentrations. Raem-
donck et al.148,149 also promoted the need for delivery vehicles that
exhibit tailored, time-controlled siRNA delivery. The concentra-
tion dependence of adverse effects, i.e., off-target silencing,
induction of an immune response and saturation of the endogenous
RNAi pathway, strongly support the need for this type of
delivery15,151. In addition, the adverse consequences of saturating
the RNAi pathway or of unwanted immune activation couldbe minimized by better controlling the intracellular siRNA
concentration152. Chemical modiﬁcations have proved to be useful
in abrogating off-target effects and unwanted stimulation of the
mammalian immune system14,15,153,154.8. Mathematical models
By illuminating the key factors that govern the duration of gene
silencing, mathematical models can help to create effective siRNA
treatment regimens. Raab and Stephanopoulos155 studied the
Table 4 Methods for particle size characterization.
Item Dynamic light scattering
(DLS)31
Atomic force microscopy
(AFM)32,33
Nanoparticle trafﬁcking
analysis (NTA)34
Fluorescence correlation
spectroscopy (FCS)35
Characteristics The most user-friendly
method, fast and
straightforward.
Produces good sizing with
narrow, homogeneous,
distributions of the
hydrodynamic diameters,
homogeneous polyplexes,
and the zeta potential of the
polyplexes.
Sample preparation is easy
and quick, visualizes and
scans the topography of the
sample, only AFM gives
information regarding the
heterogeneity of the
sample.
Sample preparation is easy
and quick, determines the
hydrodynamic diameter of
the polyplexes, good sizing
with narrow, homogeneous
distributions, requires
several optimization steps
and the results largely
depend on the operator and
the settings.
The only method suitable
for measuring polyplex
stability in 90% fetal
bovine serum.
The only method
whereby realtime analysis
of polyplex self-assembly
was possible.
Measured spontaneous
ﬂuctuation of ﬂuorescent
molecules, the
hydrodynamic radius,
ﬂuorescence labeling.
Size measurements with
FCS were done as
quickly as those
from DLS.
Determines the size of
homogeneous particles in
a manner similar to that
of NTA.
Limitations Does not discriminate
between different
morphologies of polyplexes
(rod-like or torroidal), the
dilution buffer inﬂuences
the measurements of
particle size and zeta
potential, high salt
concentrations obscure zeta
potential measurements.
DLS results do not reﬂect
reality and vary to a great
extent, the intensity of the
scattered light of big
particles hinders the
simultaneous analysis of
small particles, yields
consistent results in a
relatively short period of
time, and depends on the
distributions used for data
analysis.
Deformation of the sample,
charge interactions of the
probe with the sample
holder, only a small section
of the sample is
investigated, AFM
measurements in serum are
not possible, the real and
not the hydrodynamic, size
of the polyplexes is
determined.
Indirect sample
visualization provides
approximate particle
concentrations, gives
diameters reﬂecting the
predominant, smaller
particle fraction, while the
bigger aggregates are
neglected.
Enables indirect sample
visualization and provides
approximate particle
concentrations.
Small particles (o40 nm)
cannot be tracked with
NTA, the detection limit is
approximately 35 nm.
Had a size limitation of
200 nm the analysis is
not possible for particles
with a high number of
ﬂuorescently labeled
molecules, as the
ﬂuorescence intensity is
higher than the detection
limit.
K. Gao, L. Huang220inﬂuence of siRNA concentration and the time of siRNA
transfection relative to reporter plasmid co-transfection in mouse
hepatoma cells. By quantifying the kinetics of RNAi-based gene
silencing, they developed a model that could be used to determine
key parameters in more complex silencing experiments and
explore alternative gene silencing protocols. Takahashi et al.156
used moment analysis to evaluate the time-course of endogenous
protein expression as a function of siRNA concentration. Arciero
et al.157 used mathematical modeling to predict the immune-
system evasion of tumors and the impact of siRNA administration
directed against the immune suppressive cytokine TGF-β on tumor
growth. They predicted conditions under which siRNA treatment
could be successful in returning an aggressive, TGF-β producing
tumor to its passive, non-immune evading state. Bartlett and
Davis146 constructed a mathematical model incorporatingparameters that govern the in vivo delivery of siRNA to study
the kinetics of siRNA-mediated gene silencing. They calculated
siRNA-mediated target protein knockdown and tumor growth
inhibition to elucidate possible mechanisms of the observed effects
and provide guidelines for designing more effective siRNA-based
treatment regimens regardless of delivery methodology and tumor
type. In vivo tissue distribution and pharmacokinetics of adminis-
tered siRNA formulations (e.g., siRNA containing nanoparticles)
will have a major impact on the RNAi effect in target cells, as
discussed above. Clearly mathematical models can play a useful
role in the design of more effective siRNA delivery strategies158.
RNAi-speciﬁc parameters such as intracellular siRNA stability,
activation of RNA-induced silencing complex (RISC) and the
kinetics of siRNA–RISC–mRNA complexes must be taken into
account. When considering different siRNA delivery strategies, it
Achieving efﬁcient RNAi therapy: progress and challenges 221could also be of interest to incorporate the kinetics of siRNA
release from its formulation into predictive mathematical models
as this could well determine factor the eventual therapeutic
outcome and toxicity.9. Novel applications
9.1. Central nervous system (CNS)
There are signiﬁcant technical difﬁculties in the design, develop-
ment, and delivery of epigenetic agents into stem cell generative
zones and sites of ischemic injury in the CNS. However,
microscale and nanoscale technologies and biomaterials can over-
come the limited permeability of the blood-brain barrier and allow
sequential and selective cellular and subcellular deployment of
speciﬁc combinations of oligonucleotides, small molecules and
proteins into the CNS159–162.
To deliver epigenetic therapies into the CNS in a temporal, spatial
and cell type-speciﬁc manner, RNAi agents that are highly ﬂexible in
terms of size, surface properties and cargo-carrying abilities are being
developed. The aim is to provide the delivery systems with the
multifunctionality necessary to enable selective targeting, internaliza-
tion and release of therapeutic oligonucleotides. RNAi technologies
may allow controlled release of epigenetic small molecules, and
proteins with appropriate pharmacodynamic and pharmacokinetic
properties159–162. In addition, nanotechnologies can be functionalized
for speciﬁc imaging and active targeting applications. For example,
iron oxide and “quantum dot” nanoparticles have unique magnetic and
optical properties that enable the tracking of pathophysiological
processes involved in the study and treatment of stroke. Similarly,
using imaging techniques to monitor the activation and migration of
neural stem and progenitor cells to sites of ischemic brain injury is
necessary to better understand the process and mechanism. It is clear
that RNAi therapy combined with imaging technologies will be
important in treating CNS disease in the future. Furthermore, these
nanotechnologies can be made stimuli-sensitive to release payloads in
response to pH, near-infrared light, ultrasound and externally applied
magnetic ﬁelds.
9.2. Pulmonary siRNA application
Due to the increasing mortality and morbidity of several lung diseases,
RNAi strategies have attracted particular attention. The lung as a target
organ has several features that enable effective treatments to be
developed, including accessibility via the nasal route and by inhalation.
However, the delivery of siRNA to the lungs using non-viral systems is
restricted by a number of barriers including the mucus layer secreted by
goblet cells, apical membrane glycol-conjugates, and the airway
epithelium which has tight junctions that inhibit intracellular transport.
Despite these barriers, polyethyleneimine (PEI)112,116,117,119 has been
shown to enable the successful delivery of pDNA when it is
administered to the lungs by inhalation120–122.
9.3. Cardiac disorders
RNAi has a number of cardiac-related uses. These include
illuminating cardiac gene function and attenuating cold ischemia
injury to prolong the preservation time of donor hearts for
transplantation163. However, the main value of RNAi is in the
treatment of heart disease. Therapies aimed at regulating calciumby modulation of expression or phosphorylation state of phospho-
lamban (PLN) could restore contractility to failing hearts. As
mentioned previously, viral vectors are highly efﬁcient but have a
limited loading capacity and severe safety risks. However, nuclear
translocation o DNA encoding for shRNAs after non-viral delivery
is often inadequate such that non-viral delivery systems are mainly
used for synthetic siRNA delivery. An alternative approach to the
treatment of coronary artery disease is the delivery of potent
angiogenic factors to stimulate new vessel growth using gene
transfer109. With increased understanding of the mechanism of
endogenous RNAi, the next few years will bring new applications
of this exciting therapeutic approach.10. Combination RNAi use (coRNAi)123
RNAi monotherapies have given rise to viral mutagenesis and
cannot inhibit viral replication completely. Therefore, the primary
goal of coRNAi is to minimize the escape of viral mutants and
maintain long-term antiviral activity. This has been achieved by a
multiplex strategy resulting in long-term HIV-1 suppression in
primary cells. The strategy employed a combination of active
components including an anti-HIV shRNA, a hammerhead ribo-
zyme targeted against the HIV co-receptor chemokine receptor 5
(CCR5) and an RNA decoy of HIV-TAR124.
Recently several research groups have studied the synergistic
effects of RNAi, especially when administered with conventional
small molecule chemotherapeutics. In theory, coRNAi can beneﬁt
from synergistic effects and reduced toxicity because of the lower
dose of each drug required. Synergism of RNAi effectors can
increase the silencing effect both acutely and in the long-term but
safety concerns have been raised similar to those relating to RNAi
monotherapy. In addition, RNAi drugs given together may
compete with each other for cellular RNAi proteins to mutually
decrease their efﬁcacy125,126. A recent report by Takei et al.164
conﬁrmed a synergistic effect of RNAi triggers when combined
with paclitaxel. In this study, coadministration of low (and
essentially non-toxic) doses of paclitaxel with an effective siRNA
against midkine (MKsiRNA) in human prostate cancer xenografts
signiﬁcantly augmented the antitumor effect of MK-siRNA.11. Conclusions
Intensive investigation of the mechanism of RNAi has conﬁrmed
that siRNAs act as genuine effectors of genetic interference.
Synthetic siRNAs can be easily produced through large-scale
chemical synthesis and shown to activate gene silencing. However,
they need to be delivered into the cytoplasm of target cells to
trigger RNAi and many extra and intracellular barriers are
encountered before they reach their site of action. Therefore many
researches have been carried out on the design of novel nucleic
acid delivery systems that can maintain sufﬁcient silencing of
target genes over a prolonged period of time. Hopefully this will
lead to optimum RNAi efﬁcacy both in terms of magnitude and
duration. However, safe and long-term application of RNAi drugs
will require rigorous spatiotemporal control over intracellular
siRNA/shRNA concentrations. Macromolecules are internalized
into cells by a variety of mechanisms and their intracellular fates
are usually related to their uptake pathways. The uptake pathways
of non-viral gene complexes are usually determined not only by
the gene/carrier interaction but also by interaction between the
K. Gao, L. Huang222complex and its target cells. Model calculations have been applied
to deﬁne the optimum dosing schedule of siRNA injections to give
persistent gene silencing based on the half-life of the target protein
and the target cell division rate. Innovative technological
approaches for designing, developing, and delivering epigenetic
therapies for targeted reprogramming of endogenous pools of
neural stem progenitor cells (NSPCs), neural cells at risk, and
dysfunctional neural networks can rescue and restore neurologic
function in the ischemic brain and in pulmonary and cardiac
disorders. Stimuli-sensitive (smart) nanodevices for controlled
intracellular siRNA delivery and smart plasmids for controllable
shRNA expression may fulﬁll some of these requirements.Acknowledgment
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